Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3621035 Target Snapshot

Carbonic anhydrase, alpha family · SINGLE PROTEIN · Thiomicrospira crunogena (strain XCL-2)

44Compounds
2Assays
13Approved Drugs
44.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt Q31FD6. Use UniProt Q31FD6 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q31FD6 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Carbonic anhydrase, alpha family as ChEMBL target CHEMBL3621035, mapped to UniProt Q31FD6. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Carbonic anhydrase, alpha family
SINGLE PROTEIN · Thiomicrospira crunogena (strain XCL-2)
As of 2026-09-14
ChEMBL target ID
CHEMBL3621035
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q31FD6
carbonic anhydrase
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Carbonic anhydrase, alpha family is the right protein anchor across sources, using UniProt Q31FD6 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Labelcarbonic anhydrase
UniProt AccessionQ31FD6
Component TypeProtein
Sequence Length315 aa

carbonic anhydrase

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Carbonic anhydrase, alpha family, mapped to UniProt Q31FD6. ChEMBL maps the protein component as carbonic anhydrase. Sequence length is 315 aa.

Mapped IDQ31FD6
Review nameCarbonic anhydrase, alpha family
OrganismThiomicrospira crunogena (strain XCL-2)
Clinical Profile

Clinical Phase Distribution

13
Approved
4
Phase III
2
Phase II
Assay Mix

Activity Type Distribution

KI44.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL360356 8.6 Ki 2.5 Preclinical
CHEMBL73962 8.57 Ki 2.7 Preclinical
CHEMBL18 8.39 Ki 4.1 Approved
CHEMBL220491 8.38 Ki 4.2 Approved
CHEMBL20 8.37 Ki 4.3 Approved
CHEMBL6753 8.32 Ki 4.8 Preclinical
CHEMBL268439 8.25 Ki 5.6 Preclinical
CHEMBL218490 8.15 Ki 7.0 Approved
CHEMBL6919 7.67 Ki 21.2 Preclinical
CHEMBL17 7.61 Ki 24.8 Approved
Distribution

pChEMBL Value Distribution

0
5.0
1
5.5
14
6.0
4
6.5
9
7.0
5
7.5
6
8.0
2
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

VALDECOXIB
CHEMBL865
Approved 2001
ZONISAMIDE
CHEMBL750
Approved 2000
BRINZOLAMIDE
CHEMBL220491
Approved 1998
CELECOXIB
CHEMBL118
Approved 1998
TOPIRAMATE
CHEMBL220492
Approved 1996
DORZOLAMIDE
CHEMBL218490
Approved 1994
SULFANILAMIDE
CHEMBL21
Approved 1985
ETHOXZOLAMIDE
CHEMBL18
Approved 1982
MAFENIDE
CHEMBL419
Approved 1969
METHAZOLAMIDE
CHEMBL19
Approved 1959
HYDROCHLOROTHIAZIDE
CHEMBL435
Approved 1959
DICHLORPHENAMIDE
CHEMBL17
Approved 1958
ACETAZOLAMIDE
CHEMBL20
Approved 1953
Assay Landscape

Assay Landscape

2
Total Assays
44
Tested Compounds
1
Assay Types
Binding — 2 assays, 44 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 4 6.0
single protein format 1 40 7.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine